Payden & Rygel Amgen Inc Transaction History

Payden & Rygel

$1.16 Billion
Q4 2024

A detailed history of Payden & Rygel transactions in Amgen Inc stock. As of the latest transaction made, Payden & Rygel holds 5,300 shares of AMGN stock, worth $1.68 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

5,300

Previous 35,400 85.03%

Holding current value

$1.68 Million

Previous $11.4 Million 87.89%

% of portfolio

0.12%

Previous 0.88%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	SELL	$258.78 - $328.31 $7.79 Million - $9.88 Million	-30,100 Reduced 85.03%	5,300 $1.38 Million
Q3 2024 Nov 08, 2024	BUY	$309.38 - $337.38 $61,876 - $67,476	200 Added 0.57%	35,400 $11.4 Million
Q2 2024 Oct 07, 2024	BUY	$262.75 - $319.31 $7.86 Million - $9.55 Million	29,900 Added 564.15%	35,200 $11 Million
Q1 2024 Oct 08, 2024	BUY	$268.87 - $324.56 $6.1 Million - $7.37 Million	22,700 Added 64.49%	57,900 $16.5 Million
Q4 2023 Feb 12, 2024	BUY	$255.7 - $288.46 $1.36 Million - $1.53 Million	5,300 New	5,300 $1.53 Million
Q1 2023 May 10, 2023	BUY	$225.79 - $275.2 $15.7 Million - $19.1 Million	69,440 Added 6312.73%	70,540 $17.1 Million
Q1 2022 Apr 13, 2022	SELL	$219.27 - $242.57 $22.2 Million - $24.5 Million	-101,040 Reduced 98.92%	1,100 $266,000
Q4 2021 Feb 11, 2022	SELL	$198.88 - $227.6 $6.7 Million - $7.67 Million	-33,700 Reduced 24.81%	102,140 $23 Million
Q3 2021 Nov 15, 2021	BUY	$212.27 - $248.7 $806,626 - $945,060	3,800 Added 2.88%	135,840 $28.9 Million
Q2 2021 Aug 06, 2021	SELL	$233.58 - $259.14 $537,234 - $596,022	-2,300 Reduced 1.71%	132,040 $32.2 Million
Q1 2021 May 13, 2021	BUY	$221.91 - $258.6 $454,915 - $530,130	2,050 Added 1.55%	134,340 $33.4 Million
Q3 2020 Nov 10, 2020	BUY	$234.65 - $260.95 $12.5 Million - $13.9 Million	53,440 Added 67.77%	132,290 $33.6 Million
Q2 2020 Aug 12, 2020	BUY	$197.81 - $242.74 $336,277 - $412,658	1,700 Added 2.2%	78,850 $18.6 Million
Q1 2020 May 04, 2020	BUY	$182.24 - $241.7 $13.9 Million - $18.5 Million	76,500 Added 11769.23%	77,150 $15.6 Million
Q3 2019 Oct 30, 2019	SELL	$174.11 - $208.62 $2.21 Million - $2.65 Million	-12,680 Reduced 95.12%	650 $126,000
Q1 2019 May 08, 2019	SELL	$180.87 - $203.88 $23.3 Million - $26.2 Million	-128,600 Reduced 90.61%	13,330 $2.53 Million
Q4 2018 Jan 25, 2019	BUY	$178.4 - $208.25 $2.32 Million - $2.7 Million	12,980 Added 10.07%	141,930 $27.6 Million
Q3 2018 Nov 07, 2018	SELL	$185.29 - $208.89 $1.2 Million - $1.36 Million	-6,500 Reduced 4.8%	128,950 $26.7 Million
Q2 2018 Aug 08, 2018	BUY	$166.05 - $186.51 $66,420 - $74,604	400 Added 0.3%	135,450 $25 Million
Q1 2018 May 09, 2018	BUY	$169.43 - $198.0 $6.39 Million - $7.46 Million	37,700 Added 38.73%	135,050 $23 Million
Q4 2017 Feb 06, 2018	BUY	$168.79 - $188.59 $2.28 Million - $2.55 Million	13,500 Added 16.1%	97,350 $16.9 Million
Q3 2017 Nov 14, 2017	BUY	$167.29 - $191.0 $14 Million - $16 Million	83,850	83,850 $15.6 Million

Others Institutions Holding AMGN

# of Institutions

3,176

Shares Held

419M

Call Options Held

8.25M

Put Options Held

6.39M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $170B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Payden & Rygel, based on Form 13F filings with the SEC.

News

Stay updated on Payden & Rygel with notifications on news.

Account